MultiCell Technologies Inc (MCET)

[TPX]

Hepatitis C Pipeline Drugs and Therapeutics Market 2017

JULY 19TH, 2017

Hepatitis C pipeline drugs review h1 2017 latest report provides Hepatitis C therapeutics development by key players including AbbVie, Merck, Gilead, Novartis and other 65 key players which are discussed in report.

Hepatitis C Pipeline Therapeutics and Drugs Development Review H1 2017 report reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers Hepatitis C Therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 23, 15, 1, 52, 45 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 3, 1, 9 and 23 molecules, respectively. Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. Pharmaceutical and Healthcare latest pipeline guide Hepatitis C – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Get Discount on report at http://www.reportsnreports.com/contacts/discount.aspx?name=983987 .

Companies involved in Hepatitis C Pipeline Therapeutics and Drugs Development analysed are ... MultiCell Technologies Inc ...

https://www.medgadget.com/2017/07/hepatitis-c-pipeline-drugs-and-therapeutics-market-2017.html